Iron metabolism in blood donors
Authors:
L. Sulovská 1; D. Holub 2; D. Galuszková 3; I. Sulovská 3; M. Hajdúch 2; M. Horváthová 4; D. Pospíšilová 1
Authors‘ workplace:
Dětská klinika, Fakultní nemocnice a Lékařské fakulty Univerzity Palackého v Olomouci
1; Ústav molekulární a translační medicíny, Olomouc
2; Transfuzní oddělení, Fakultní nemocnice a Lékařské fakulty Univerzity Palackého v Olomouci
3; Ústav biologie Lékařské fakulty Univerzity Palackého v Olomouci
4
Published in:
Transfuze Hematol. dnes,21, 2015, No. 4, p. 193-199.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Introduction:
Iron metabolism is closely related to bone marrow erythropoietic activity. Blood donation alters iron homeostasis and may lead to depletion of donor iron stores. The aim of this study was to evaluate selected parameters of iron metabolism and their role in the prevention of iron deficiency in blood donors.
Material and methods:
Blood count, serum iron, ferritin and hepcidin levels were evaluated in blood donors who met the criteria for blood donation in accordance with the Recommendation of the Society for Transfusion Medicine. A group of 117 blood donors (64 men and 53 women) who were eligible to donate blood were tested. The hepcidin level was determined using proteomic analysis based on reverse liquid chromatography coupled with mass spectrometry (LC-MS).
Results:
Men had a significantly higher erythrocyte count, haemoglobin, haematocrit and ferritin than women. Ferritin level correlated positively with the level of hepcidin in both men and women. Six men (9.52%) and nine women (17.64%) had serum ferritin below 12 ng/ml. Markedly reduced levels of hepcidin (below 2.5 ng/ml) were detected in 18 men (28%) and 5 women (9.8%).
Conclusion:
Hepcidin reflects better iron required for erythropoiesis and it can be used as a marker for monitoring iron status in blood donors.
Key words:
hepcidin, iron metabolism, blood donation, iron deficiency
Sources
1. Doig K. Disorders of iron and heme metabolism. In Rodak BF, Fritsma GA, Keohane OA. Hematology: clinical principles and applications. 4. vyd., Elsevier, Missouri, 2012; 271–284.
2. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004; 306(5704): 2090–2093.
3. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program, 2011; 2011: 538–542.
4. Waldvogel-Abramovski S, Waeber G, Gassner C, et al. Iron and transfusion medicine. Blood Rev 2013; 27(6): 289–295.
5. Cable RG, Glynn SA, Kiss JE, et al. NHLBI Retrovirus Epidemiology Donor Study-II. Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study. Transfusion 2011; 51(3): 511–522.
6. Baart AM, de Kort WL, Moons KG, Atsma F, Vergouwe Y. Zinc protoporphyrin levels have added value in the prediction of low hemoglobin deferral in whole blood donors. Transfusion 2013; 53(8): 1661–1669.
7. Pasricha SR, McQuilten ZK, Keller AJ, Wood EM. Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. Transfusion 2011; 51(12): 2709–2713.
8. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008; 112(10): 4292–4297.
9. Young MF, Glahn RP, Ariza-Nieto M, et al. Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women. Am J Clin Nutr 2009; 89(2): 533–538.
10. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008; 93(10): 1473–1479.
11. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010 Sep; 5(9): 1681–1690.
12. Mojzikova R, Koralkova P, Holub D, et al. Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios. Br J Haematol 2014; 165(4): 556–563.
13. Pospíšilová D, Houda J, Holub D, et al. Význam stanovení hladiny hepcidinu u vybraných typů anémií v dětském věku. Transfuze Hematol dnes 2012; 19(2): 58–65.
14. Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol 2012; 87(10): 977–983.
15. Vyhláška MZ ČR č. 143/2008 Sb., o stanovení bližších požadavků pro zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi).
16. Doporučení Společnosti pro transfuzní lékařství ČLS JEP č. STL2007_03: Posuzování způsobilosti k dárcovství krve a krevních složek, verze 7, 12. 4. 2007, dostupné z: http://www.transfuznispolecnost.cz/index.php?page=dokumenty&identifikator_kategorie=DOPORUCENE_POSTUPY.
17. Výroční zpráva zařízení transfuzní služby 2013, MZ ČR, dostupné z: http://www.mzcr.cz/dokumenty/zprava-o-cinnosti-zarizeni-transfuzni-sluzby-za-rok-2013_9292_1952_3.html.
18. Hillgrove T, Moore V, Doherty K, Ryan P. The impact of temporary deferral due to low hemoglobin: future return, time to return, and frequency of subsequent donation. Transfusion 2011; 51(3): 539–547.
19. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 2010; 9: 4.
20. Murray-Kolb LE, Beard JL. Iron treatment normalizes cognitive functioning in young women. Am J Clin Nutr 2007 Mar; 85(3): 778–787.
21. Hinton PS. Iron and the endurance athlete. Appl Physiol Nutr Metab 2014; 39(9): 1012–1018.
22. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108(12): 3730–3735.
23. Baart AM, van Noord PA, Vergouwe Y, et al. High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion 2013; 53(8): 1670–1677.
24. Rigas AS, Sørensen CJ, Pedersen OB, et al. Predictors of iron levels in 14,737 Danish blood donors: results from the Danish Blood Donor Study. Transfusion 2014; 54: 789–796.
25. Goldman M, Uzicanin S, Scalia V, O’Brien SF. Iron deficiency in Canadian blood donors. Transfusion 2014; 54(3 Pt 2): 775–779.
26. Mast AE. Low hemoglobin deferral in blood donors. Transfus Med Rev 2014; 28(1): 18–22.
27. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program 2008: 151–158.
28. Sanad M, Gharib AF. Urinary hepcidin level as an early predictor of iron deficiency in children: A case control study. Ital J Pediatr 2011; 37: 37.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2015 Issue 4
Most read in this issue
- Iron metabolism in blood donors
- Hereditary amyloidosis – aetiology, clinical features and treatment options
- The cytomorphology and immunophenotype of mantle-cell lymphoma
- The role of rituximab maintenance in elderly patients with mantle cell lymphoma in first remission – single centre experience